Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and DRG oncology experts’ assumptions.
Non-Small-Cell Lung Cancer - Geographic Focus: China - Non-Small-Cell Lung Cancer | China In-Depth | China
Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, with multiple targeted and biomarker-driven therap...
Non-Small-Cell Lung Cancer - Current Treatment - Detailed Expanded Analysis: Treatment Sequencing (EU5)
This report is available to find out more click the link and fill out the form to get more details.
Non-Small-Cell Lung Cancer - Landscape & Forecast - Disease Landscape & Forecast
Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need remains a key area of focus for drug developers.
Non-Small-Cell Lung Cancer - Current Treatment - Detailed, Expanded Analysis (EU5) - 2020
The current treatment algorithm for non-small-cell lung cancer (NSCLC) is rapidly evolving. The increasing number of biomarker-driven therapies has r...